Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation

Journal of the American Society of Nephrology

Volumn 14, Issue 9, 2003, Pages 2381-2386

  Knoll, Greg A ^a,d   Macdonald, Ian ^b   Khan, Asmat ^c   Van Walraven, Carl ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; ORTHOCLONE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HUMAN; INFECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; VOMITING;

EID: 0042536429     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000079616.71891.F5     Document Type: Article

References (18)

1. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C: Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 63: 39-47, 1997
2. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345: 1321-1325, 1995
3. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029-1037, 1996
4. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225-232, 1995
5. Squifflet JP, Backman L, Claesson K, Dietl KH, Ekberg H, Forsythe JL, Kunzendorf U, Heemann U, Land W, Morales JM, Muhlbacher F, Talbot D, Taube D, Tyden G, van Hooff J, Schleibner S, Vanrenterghem Y: Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 72: 63-69, 2001
6. Roth D, Colona J, Burke GW, Ciancio G, Esquenazi V, Miller J: Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 65: 248-252, 1998
7. Mourad M, Malaise J, Chaib ED, De Meyer M, Konig J, Schepers R, Squifflet JP, Wallemacq P: Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 47: 88-94, 2001
8. Pelletier RP, Akin EB, Bumgardner GL, Rajab A, Elkhammas EA, Henry ML, Ferguson RM: Mycophenolate mofetil dose reduction influences clinical outcome following kidney transplantation [Abstract]. Am J Transplant 2[Suppl 3]: 467, 2003
9. Wolfe RA, Strawderman RL: Logical and statistical fallacies in the use of Cox regression models. Am J Kidney Dis 27: 124-129, 1996
10. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
11. Hariharan S, Johnson C, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the united states, 1988 to 1996. N Engl J Med 342: 605-612, 2000
12. Miller J, Mendez R, Pirsch JD, Jensik SC: Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Transplantation 69: 875-880, 2000
13. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69: 2405-2409, 2000
14. EBPG Expert Group on Renal Transplantation: European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.9.2. Haematological complications: Leukopenia. Nephrol Dial Transplant 17[Suppl]: 49, 2002
15. Huebner G, Karthaus M, Pethig K, Freund M, Ganser A: Myelodysplastic syndrome and acute myelogenous leukemia secondary to heart transplantation. Transplantation 70: 688-690, 2000
16. Van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hene RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ: A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68: 261-266, 1999
17. Meier-Kriesche HU, Ojo A, Magee JC, Cibrik DM, Hanson JA, Leichtman AB, Kaplan B: African-American renal transplant recipients experience decreased risk of death due to infection: Possible implications for immunosuppressive strategies. Transplantation 70: 375-379, 2000
18. Neylan JF: Immunosuppressive therapy in high-risk transplant patients: Dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 64: 1277-1282, 1997